PhenoNet: Identification of key networks associated with disease phenotype

Bioinformatics

Volumn 30, Issue 17, 2014, Pages 2399-2405

  Ben Hamo, Rotem ^a   Gidoni, Moriah ^a   Efroni, Sol ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHENOTYPE; PROTEIN ANALYSIS; TRIPLE NEGATIVE BREAST CANCER;

ALGORITHMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; NEOPLASMS; PHENOTYPE; PROTEIN INTERACTION MAPPING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907033478     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btu199     Document Type: Article

References (44)

1. Altay, G. and Emmert-Streib, F. (2011) Structural influence of gene networks on their inference: analysis of C3NET. Biol. Direct, 6, 31.
2. Antonov, A.V. et al. (2009) PPI spider: a tool for the interpretation of proteomics data in the context of protein-protein interaction networks. Proteomics, 9, 2740-2749.
3. Ben-Hamo, R. and Efroni, S. (2012a) Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst. Biol., 6, 3.
4. Ben-Hamo, R. and Efroni, S. (2012b) Correction: gene expression and networkbased analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med., 4, 87.
5. Ben-Hamo, R. and Efroni, S. (2013) Network as biomarker: quantifying transcriptional co-expression to stratify cancer clinical phenotypes. Syst. Biomed., 1, 35-41.
6. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol., 57, 289-300.
7. Correia, A.L. and Bissell, M.J. (2012) The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat., 15, 39-49.
8. Dedeurwaerder, S. et al. (2011) DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol. Med., 3, 726-741.
9. Efroni, S. et al. (2011) Detecting cancer gene networks characterized by recurrent genomic alterations in a population. PLoS One, 6, e14437.
10. Ein-Dor, L. et al. (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA, 103, 5923-5928.
11. Emmert-Streib, F. et al. (2012) Harnessing the complexity of gene expression data from cancer: from single gene to structural pathway methods. Biol. Direct, 7, 44.
12. Fan, W.W. et al. (2004) TBX3 and its isoform TBX32a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res., 64, 5132-5139.
13. Fernando, R.I. et al. (2010) The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J. Clin. Invest., 120, 533-544.
14. Fröhlich H (2011) Network based consensus gene signatures for biomarker discovery in breast cancer. PLoS One 6 e25364.
15. Gelenbe, E. (2007) Steady-state solution of probabilistic gene regulatory networks. Phys. Rev. E Stat. Nonlin. Soft Matter Phys., 76 (Pt. 1), 031903.
16. Greenblum, S.I. et al. (2011) The PathOlogist: an automated tool for pathway-centric analysis. BMC Bioinformatics, 12, 133.
17. Hermeking, H. (2003) The 14-3-3 cancer connection. Nat. Rev. Cancer, 3, 931-943.
18. Jenssen, T.K. et al. (2002) Associations between gene expressions in breast cancer and patient survival. Hum Genet, 111, 411-420.
19. Joshi-Tope, G. et al. (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res., 33, D428-D432.
20. Khatri, P. et al. (2012) Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput. Biol., 8, e1002375.
21. Kim, H. and Gelenbe, E. (2012) Stochastic gene expression modeling with Hill function for switch-like gene responses. IEEE/ACM Trans. Comput. Biol. Bioinform., 9, 973-979.
22. Lee, E. et al. (2008) Inferring pathway activity toward precise disease classification. PLoS Comput. Biol., 4, e1000217.
23. Li, J. et al. (2012) SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data. Nucleic Acids Res., 40, W123-W126.
24. Ogata, H. et al. (1999) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res., 27, 29-34.
25. Olson, J.E. et al. (2011) Centrosome-related genes, genetic variation, and risk of breast cancer. Breast Cancer Res. Treat., 125, 221-228.
26. Peri, S. et al. (2003) Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res., 13, 2363-2371.
27. Pierobon, M. et al. (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin. Colorectal Cancer, 8, 110-117.
28. Roselli, M. et al. (2012) Brachyury, a driver of the epithelial- mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin. Cancer Res., 18, 3868-3879.
29. Sabatier, R. et al. (2011a) Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One, 6, e27656.
30. Sabatier, R. et al. (2011b) A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res. Treat., 126, 407-420.
31. Schaefer, C.F. et al. (2009) PID: the pathway interaction database. Nucleic Acids Res., 37, D674-D679.
32. Song, Y. et al. (2012) Expression of 14-3-3 in patients with breast cancer: correlation with clinicopathological features and prognosis. Cancer Epidemiol., 36, 533-536.
33. Stark, C. et al. (2011) The BioGRID Interaction Database: 2011 update. Nucleic Acids Res., 39, D698-D704.
34. Stockmans, G. et al. (2008) Triple-negative breast cancer. Curr. Opin. Oncol., 20, 614-620.
35. Su, J. et al. (2009) Accurate and reliable cancer classification based on probabilistic inference of pathway activity. PLoS One, 4, e8161.
36. Teschendorff, A.E. et al. (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer, 10, 604.
37. Theocharidis, A. et al. (2009) Network visualization and analysis of gene expression data using BioLayout Express (3D). Nat. Protoc., 4, 1535-1550.
38. Trapnell, C. et al. (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-1111.
39. Trapnell, C. et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol., 28, 511-515.
40. Vaske, C.J. et al. (2010) Inference of patient-specific pathway activities from multidimensional cancer genomics data using PARADIGM. Bioinformatics, 26, i237-i245.
41. Venet, D. et al. (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol., 7, e1002240.
42. Wang, Y.C. and Chen, B.S. (2011) A network-based biomarker approach for molecular investigation and diagnosis of lung cancer. BMC Med. Genomics, 4, 2.
43. Wilker, E. and Yaffe, M.B. (2004) 14-3-3 proteins - a focus on cancer and human disease. J. Mol. Cell. Cardiol., 37, 633-642.
44. Ziogas, D.E. et al. (2011) From traditional molecular biology to network oncology. Future Oncol., 7, 155-159.